Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Phase 3

Active, not recruiting

Conditions: Primary Progressive Multiple Sclerosis

Interventions: Drug: Tolebrutinib
Drug: Placebo

First Posted Date: 2020-07-07

Last Posted Date: 2025-01-13

Lead Sponsor: Sanofi

Target Recruit Count: 767

Registration Number: NCT04458051

Locations: 🇺🇸
Multiple Sclerosis Center- Site Number : 8400143, Los Angeles, California, United States
🇺🇸
University of San Francisco, Sandler Neurosciences Center- Site Number : 8400137, San Francisco, California, United States
🇺🇸
Neurology Associates, PA- Site Number : 8400004, Maitland, Florida, United States

and more 274 locations

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Dupilumab SAR231893
Drug: Inhaled Corticosteroid
Drug: Inhaled Long-Acting Beta Agonist
Drug: Inhaled Long-Acting Muscarinic Antagonist
Drug: Placebo

First Posted Date: 2020-07-02

Last Posted Date: 2025-05-29

Lead Sponsor: Sanofi

Target Recruit Count: 935

Registration Number: NCT04456673

Locations: 🇺🇸
Radiance Clinical Research Site Number : 8400029, Lampasas, Texas, United States
🇺🇸
Cullman Research Center, LLC Site Number : 8400095, Cullman, Alabama, United States
🇺🇸
Pulmonary & Sleep Associates of Jasper PC Site Number : 8400090, Jasper, Alabama, United States

and more 331 locations

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

Phase 4

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Dupilumab SAR231893

First Posted Date: 2020-06-25

Last Posted Date: 2022-07-22

Lead Sponsor: Sanofi

Target Recruit Count: 52

Registration Number: NCT04447417

Locations: 🇺🇸
Investigational Site Number 8400001, Denver, Colorado, United States
🇨🇦
Investigational Site Number 1240001, Montreal, Canada

A National Study in Patients With Unexplained Splenomegaly

Completed

Conditions: Gaucher Disease
Splenomegaly

First Posted Date: 2020-06-12

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 506

Registration Number: NCT04430881

Locations: 🇫🇷
Investigational site France, France, France

Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Phase 1

Terminated

Conditions: Metastatic Neoplasm

Interventions: Drug: Vociprotafib
Drug: SAR442720
Drug: Pembrolizumab
Drug: Adagrasib

First Posted Date: 2020-06-05

Last Posted Date: 2025-05-29

Lead Sponsor: Sanofi

Target Recruit Count: 65

Registration Number: NCT04418661

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center- Site Number : 8400001, Houston, Texas, United States
🇦🇷
Investigational Site Number : 0320003, Rosario, Santa Fe, Argentina
🇦🇷
Investigational Site Number : 0320001, Buenos Aires, Argentina

and more 17 locations

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Phase 3

Completed

Conditions: Secondary Progressive Multiple Sclerosis

Interventions: Drug: Placebo to match Tolebrutinib
Drug: Tolebrutinib

First Posted Date: 2020-06-02

Last Posted Date: 2025-02-03

Lead Sponsor: Sanofi

Target Recruit Count: 1131

Registration Number: NCT04411641

Locations: 🇺🇸
University of Alabama MS Center-Site Number:8400013, Birmingham, Alabama, United States
🇺🇸
Center for Neurology and Spine-Site Number:8400089, Phoenix, Arizona, United States
🇺🇸
Arcadia Neurology Center-Site Number:8400070, Arcadia, California, United States

and more 303 locations

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

Phase 3

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Teriflunomide HMR1726
Drug: Tolebrutinib
Drug: Placebo to match Teriflunomide
Drug: Placebo to match Tolebrutinib

First Posted Date: 2020-06-01

Last Posted Date: 2024-04-19

Lead Sponsor: Sanofi

Target Recruit Count: 900

Registration Number: NCT04410991

Locations: 🇺🇸
CHI Saint Joseph Medical Group Neurology-Site Number:8400110, Lexington, Kentucky, United States
🇮🇳
Investigational Site Number :3560005, Chandigarh, India
🇷🇺
Investigational Site Number :6430007, Moscow, Russian Federation

and more 183 locations

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Phase 3

Active, not recruiting

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Teriflunomide HMR1726
Drug: Tolebrutinib
Drug: Placebo to match Teriflunomide
Drug: Placebo to match Tolebrutinib

First Posted Date: 2020-06-01

Last Posted Date: 2024-04-19

Lead Sponsor: Sanofi

Target Recruit Count: 900

Registration Number: NCT04410978

Locations: 🇺🇸
University of Texas Southwestern Medical Center-Site Number:8400077, Dallas, Texas, United States
🇺🇸
Meridian Clinical Research-Site Number:8400003, Savannah, Georgia, United States
🇧🇬
Investigational Site Number :1000001, Sofia, Bulgaria

and more 176 locations

Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: TERIFLUNOMIDE

First Posted Date: 2020-06-01

Last Posted Date: 2022-04-13

Lead Sponsor: Sanofi

Target Recruit Count: 82

Registration Number: NCT04410965

Locations: 🇨🇳
Investigational Site Number, China, China

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Phase 1

Active, not recruiting

Conditions: Neoplasm Malignant

Interventions: Drug: SAR442257

First Posted Date: 2020-05-26

Last Posted Date: 2025-03-21

Lead Sponsor: Sanofi

Target Recruit Count: 47

Registration Number: NCT04401020

Locations: 🇳🇴
Investigational Site Number : 5780001, Oslo, Norway
🇳🇴
Investigational Site Number : 5780101, Oslo, Norway
🇨🇿
Investigational Site Number : 2030001, Ostrava - Poruba, Czechia

and more 13 locations

Home Terms & Conditions Privacy Policy